|
|
|
|
|
Phenelzine
drug data and news
Phenelzine drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Phenelzine | ||
| Brand Names/Synonyms | Beta-Phenylethylhydrazine; CHEMBANK3273; Fenelzina [Inn-Spanish]; Fenelzyna; Fenelzyna [Polish]; Fenelzyne; Fenelzyne [Polish]; Hydrazine, Phenethyl-; Nardil; Phenalzine; Phenelezine; Phenelzine; Phenelzinum [Inn-Latin]; Phenethylhydrazine; Phenylethyl Hydrazine-Hcl; Phenylethylhydrazine; Stinerval; W-1544; W1544 | ||
| Indication | Indicated in the treatment of depression. | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Phenelzine belongs to a class of antidepressants called monoamine oxidase inhibitors (MAOIs). Phenelzine works by irreversibly blocking the action of a chemical substance known as monoamine oxidase (MAO) in the nervous system. Within neurons, MAO appears to regulate the levels of monoamines released upon synaptic firing. Since depression is associated with low levels of monoamines, the inhibition of MAO serves to ease depressive symptoms. | ||
| Mechanism Of Action | The irreversible inhibition of MAO by Phenelzine causes an increase in the levels of serotonin, norepinephrine, and dopamine in the neuron, relieving depressive symptoms. | ||
| Phenelzine News (When available) |
Medicine mix kills man, 40 May 4, 2006 | ||
| Dosage Forms | TABLET | ||
| Drug_Category | Antidepressants; ATC:N06AF03 | ||
| Absorption | Readily absorbed after oral administration. | ||
| Interactions |
Interactions for Phenelzine: In patients receiving nonselective monoamine oxidase (MOA) inhibitors in combination with serotoninergic agents (e.g., dexfenfluramine, fluoxetine, fluvoxamine, paroxetine, sertraline, venlafexine) there have been reports of serious, sometimes fatal, reactions. Because Nardil is a monoamine oxidase (MAO) inhibitor, Nardil should not be used concomitantly with a serotoninergic agent. | ||
| Toxicity | Drowsiness, dizziness, faintness, irritability, hyperactivity, agitation, severe headache, hallucinations, trismus, opisthotonos, convulsions and coma, rapid and irregular pulse, hypertension, hypotension and vascular collapse, precordial pain, respiratory depression and failure, hyperpyrexia, diaphoresis, and cool, clammy skin. | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 2-hydrazinylethylbenzene | ||
| Chemical Formula | C8H12N2 | ||
| Molecular Weight | 136.194 g/mol | ||
| Smiles String | C1=CC=C(C=C1)CCNN | ||
| Melting Point | < 25 °C | ||
| Water Solubility | Not Available | ||
| State | Liquid | ||
| LogP/Hphobicity | 0.769 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Hepatic. Acetylation of phenelzine appears to be a minor metabolic pathway. Beta-Phenylethylamine is a metabolite of phenelzine, and there is indirect evidence that phenelzine may also be ring-hydroxylated and N-methylated. | ||
| Half Life | Not Available | ||
| Protein Binding [%] | Not Available | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Phenelzine.html http://www.rxlist.com/cgi/generic2/phenelzine.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00099 | ||
| CAS Registry Number | 51-71-8 | ||
| KEGG Compound ID | C07430 | ||
| PubChem ID | SID:9634 | ||
| PharmGKB ID | PA450903 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 476552 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |